Medical Devices
Point-of-Care Testing (POCT) Devices Market Size, 2024-2033
USD Billion
The figures are in the full report. Request a free sample ↗
Market overview
| Study Period | 2024 - 2033 |
|---|---|
| Historic Year | 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2033 |
| Market Size (Base Year) | USD 40.0 Billion |
| Market Size (Forecast Year) | USD 63.8 Billion |
| Growth Rate (CAGR) | 6.0 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Pages from the sample report. Figures are shown as XX here; the full report has them.
See the full sample: Request a free sample ↗
This report covers the point-of-care testing (POCT) devices market: diagnostic tests and devices used at or near the patient, outside central laboratories, including glucose monitoring devices, blood gas and electrolyte analysers, coagulation monitors and haematology, cardiovascular, infectious disease and pregnancy and fertility tests, used in hospitals and clinics, ambulatory care, homes and diagnostic centres. The market is valued at manufacturers' selling prices.
Point-of-care tests give results within minutes, allowing faster treatment decisions in emergency rooms, intensive care, doctors' offices, pharmacies and at home.
The rising number of people with diabetes and the spread of continuous glucose monitors, including to people with type 2 diabetes and over-the-counter users, make glucose monitoring the largest and fastest-growing part of the market.
Hospitals and clinics use point-of-care tests to speed diagnosis in emergency and critical care, and health systems are moving testing into pharmacies, clinics and homes. New molecular tests bring laboratory-quality infectious disease testing to the point of care.
However, reimbursement limits, quality and accuracy requirements, price competition in blood glucose strips and the fall in respiratory testing after the pandemic weigh on parts of the market.
The global Point-of-Care Testing (POCT) Devices market is mainly classified based on product type and end user. By product type, the market is segmented into coagulation monitoring devices, blood gas and electrolyte analysers, haematology testing kits, cardiovascular testing kits, infectious disease testing kits, pregnancy and fertility testing kits, glucose monitoring devices and others. By end user, it covers hospitals and clinics, ambulatory care settings, homecare settings, diagnostic centres and others.
Glucose monitoring devices account for about half of the market, led by continuous glucose monitors, followed by infectious disease tests, blood gas and electrolyte analysers, and cardiovascular and coagulation tests.
Homecare settings account for the largest share because of glucose monitoring and pregnancy tests, while hospitals and clinics are the largest users of professional point-of-care analysers.
North America is the largest market, led by the United States, with high use of continuous glucose monitors and point-of-care testing in hospitals, clinics and pharmacies.
Europe is the second-largest market with strong glucose monitoring and hospital point-of-care use. Asia-Pacific is expected to grow fastest as diabetes rises and healthcare access expands in China and India, while South America and the Middle East and Africa are smaller but growing markets.
Some of the major competitors in the global Point-of-Care Testing (POCT) Devices market include Abbott Laboratories, Dexcom, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Danaher Corporation (Radiometer, Cepheid), Werfen, QuidelOrtho Corporation, bioMérieux SA, Becton, Dickinson and Company (BD), Medtronic (MiniMed), Ascensia Diabetes Care, Nova Biomedical Corporation, Sekisui Diagnostics LLC, Nipro Corporation, Sysmex Corporation, and Sinocare.
The Point-of-Care Testing (POCT) Devices market is moderately concentrated. Abbott and Dexcom lead in continuous glucose monitoring, Roche, Ascensia and Chinese makers in blood glucose meters, and Abbott, Roche, Siemens Healthineers, Danaher's Radiometer and Cepheid, Werfen, QuidelOrtho, bioMérieux and BD in professional point-of-care testing.
Ans: The Point-of-Care Testing (POCT) Devices market was valued at USD 40.0 billion in 2025 and is projected to reach USD 63.8 billion by 2033, at a CAGR of 6.0% during the forecast period.
Ans: Continuous glucose monitoring for type 2 diabetes and over-the-counter use, molecular point-of-care tests, pharmacy testing and connected devices are major opportunities.
Ans: The rising number of people with diabetes and the shift of testing closer to patients are the main growth drivers.
Ans: North America is expected to have the largest share, while Asia-Pacific is expected to grow fastest.
Ans: Glucose monitoring devices are expected to dominate the market.
In September 2025 the US Department of Commerce opened a national security investigation into imports of medical equipment, devices, consumables and protective equipment. Point-of-care testing relies heavily on imported test strips, cartridges, sensors and analysers, so tariffs resulting from the investigation could raise costs.
Leading suppliers have so far managed tariff effects through pricing and local production, and large manufacturers have expanded US production of glucose sensors and diagnostic tests.
Demand for continuous glucose monitors remains strong as use spreads to people with type 2 diabetes and over-the-counter sensors, while demand for rapid respiratory tests has fallen back after the pandemic years.
This report assumes that any tariffs are partly absorbed and partly passed on without a lasting fall in demand, and treats broad device tariffs and reimbursement changes as the main risks.
Backed by 1 million+ hours of research experience across the industries we cover.
Domains covered
Countries covered
Committed to timely delivery
Projects delivered